- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Trulicity Pen
Synonyms :
dulaglutide
Class :
Incretin mimetics
Dosage Forms & Strengths
Solution
0.75mg/0.5mL
1.5mg/0.5mL
3mg/0.5mL
4.5mg/0.5mL
Dosage Forms & Strengths
Solution
0.75mg/0.5mL
1.5mg/0.5mL
3mg/0.5mL
4.5mg/0.5mL
it increases the adverse effects caused due to eptinezumab
Beta-Blockers increase the effect of hypoglycemia of insulins
Beta-Blockers increase the effect of hypoglycemia of insulins
Beta-Blockers increase the effect of hypoglycemia of insulins
Beta-Blockers increase the effect of hypoglycemia of insulins
Beta-Blockers increase the effect of hypoglycemia of insulins
may increase the effect of insulins
may increase the effect of insulins
may increase the effect of insulins
antiviral Agents may enhance the hypoglycemic effect of anti-diabetic Agents
antiviral Agents may enhance the hypoglycemic effect of anti-diabetic Agents
antiviral Agents may enhance the hypoglycemic effect of anti-diabetic Agents
antiviral Agents may enhance the hypoglycemic effect of anti-diabetic Agents
antiviral Agents may enhance the hypoglycemic effect of anti-diabetic Agents
may diminish the therapeutic effect of antidiabetic Agents
may diminish the therapeutic effect of antidiabetic Agents
may diminish the therapeutic effect of antidiabetic Agents
may diminish the therapeutic effect of antidiabetic Agents
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
it increases the effect of hypoglycemia of antidiabetic agents
it increases the effect of hypoglycemia of antidiabetic agents
it increases the effect of hypoglycemia of antidiabetic agents
it increases the effect of hypoglycemia of antidiabetic agents
it increases the effect of hypoglycemia of antidiabetic agents
it increases the efficacy of antidiabetic agents
may increase the hypoglycaemic effect
may enhance the hypoglycemic effect of beta blockers
Frequency defined
Increased amylase (20%)
Diarrhea (7-12.6%)
Increased lipase (14%)
Nausea (12.4-21.1%)
Vomiting (5.6-9.3%)
Fatigue (4.2-5.6%)
Decreased appetite (4.9-8.6%)
Dyspepsia (2.3-5.8%)
Severe hypoglycemia (2.7-3.4%)
Constipation (3.7-3.9%)
Flatulence (1.4-3.4%)
Abdominal pain (6.5-9.4%)
Abdominal distension (2.3-2.9%)
Sinus tachycardia (2.8-3%)
Gastroesophageal reflux disease (1.7-2%)
Eructation (0.6-1.6%)
AV block (0.9-1.7%)
Injection-site reactions
Cholelithiasis
Cholecystitis
Hypersensitivity
Pancreatitis
Black Box Warning
dulaglutide carries a warning for the risk of thyroid C-cell tumors in animal studies. This warning is based on the findings of thyroid C-cell tumors in rodents treated with other GLP-1 receptor agonists.
dulaglutide should not be used in people with a personal or family history of medullary thyroid carcinoma (MTC) or in people with multiple endocrine neoplasia syndrome type 2 (MEN 2).
People taking dulaglutide should also be advised to report any symptoms of thyroid tumors, such as a lump in the neck, difficulty swallowing, hoarseness, or persistent cough, to their healthcare provider.
Regular monitoring of thyroid function and imaging is not recommended for people taking dulaglutide, except in cases of suspected MTC or MEN 2.
Contraindication /Caution:
Pregnancy consideration:
Pregnancy category: NA
Lactation:
The excretion of drug into human milk is unknown
Pregnancy Categories:
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
Category B: There were lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
dulaglutide is a GLP-1 receptor agonist that binds to and activates the GLP-1 receptor in pancreatic beta-cells, which results in the release of insulin in response to high blood sugar levels.
It also inhibits the secretion of glucagon, a hormone that increases blood sugar levels by promoting the production of glucose in the liver. dulaglutide also slows down gastric emptying and reduces appetite, which can lead to weight loss.
Pharmacodynamics:
In pancreatic beta-cells, dulaglutide stimulates the release of insulin in response to high blood sugar levels. This effect helps lower blood sugar levels in people with type 2 diabetes and inhibits the secretion of glucagon, a hormone that raises blood sugar levels by promoting glucose production in the liver.
By inhibiting glucagon secretion, dulaglutide helps to further reduce blood sugar levels in people with type 2 diabetes. Overall, the pharmacodynamics of dulaglutide involves its effects on blood sugar control, weight loss, and cardiovascular and renal protection in people with type 2 diabetes.
Pharmacokinetics:
Absorption
Absolute SC bioavailability for 3 mg and 4.5 mg doses estimated to be like 1.5 mg, although not been specifically studied and concentrations increased proportional to dose from 0.75-4.5 mg.
Distribution
Distributed about 3.09 L through central way and 5.98 L through peripheral way.
Metabolism
Degraded into its component amino acids by general protein catabolism pathways.
Elimination and Excretion
The half-life is around 5 days and clearance recorded as 0.142 L/hr.
Administration:
dulaglutide is administered by subcutaneous injection once a week. The injection can be given at any time of the day, with or without food. The recommended starting dose is 0.75 mg once a week, which can be increased to 1.5 mg once a week after four weeks if needed to achieve blood sugar control.
Before administering dulaglutide, it is important to check the medication label and ensure that the solution is clear and free of particles. The injection site should also be cleaned with an alcohol swab to reduce the risk of infection.
Patient information leaflet
Generic Name: dulaglutide
Pronounced: DOO-la-GLOO-tide
Why do we use dulaglutide?
dulaglutide is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.
dulaglutide is also used to help reduce the risk of serious heart problems such as heart attack or stroke in adults who have type 2 diabetes and heart disease.